Thoracic Cancer (Jul 2024)

CircSLC25A16 facilitates the development of non‐small‐cell lung cancer through the miR‐335‐5p/CISD2 axis

  • Yu Fu,
  • Bin Chen,
  • Tao Gao,
  • Zhenglong Wang

DOI
https://doi.org/10.1111/1759-7714.15163
Journal volume & issue
Vol. 15, no. 19
pp. 1490 – 1501

Abstract

Read online

Abstract Background Non‐small‐cell lung cancer (NSCLC) is a common malignancy with high morbidity and mortality. Circular RNAs are widely involved in NSCLC progression. However, the mechanism of circSLC25A16 in NSCLC has not been reported. Methods The expressions of circSLC25A16, microRNA‐335‐5p (miR‐335‐5p), and CDGSH iron–sulfur domain‐containing protein 2 (CISD2) were monitored by quantitative real‐time fluorescence polymerase chain reaction. Western blot was also carried out to measure the protein levels of CISD2, hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA). For functional analysis, cell counting kit‐8 assay, 5‐ethynyl‐2′‐deoxyuridine, flow cytometry, transwell, and wound healing assays were utilized to examine cell proliferation, apoptosis, and migration. Glucose uptake and lactate production were detected using commercial kits. The relationship between miR‐335‐5p and circSLC25A16 or CISD2 was verified by dual‐luciferase reporter and RNA immunoprecipitation assays. Furthermore, tumor xenograft was established to explore the function of circSLC25A16 in vivo. Results CircSLC25A16 and CISD2 were overexpressed in NSCLC, but miR‐335‐5p was downregulated. CircSLC25A16 acted as a miR‐335‐5p sponge, and silencing of circSLC25A16 arrested cell proliferation, migration, and glycolysis, and promoted apoptosis, but these impacts were resumed by miR‐335‐5p inhibition. CISD2 was a miR‐335‐5p target, and overexpression of CISD2 abolished the suppressive function of miR‐335‐5p mimic on the malignant behavior of NSCLC cells. CircSLC25A16 could adsorb miR‐335‐5p to mediate CISD2 expression. Additionally, silencing circSLC25A16 restrained the growth of NSCLC tumor xenograft in vivo. Conclusion CircSLC25A16 facilitated NSCLC progression via the miR‐335‐5p/CISD2 axis, implying that circSLC25A16 may serve as a novel biomarker for NSCLC treatment.

Keywords